Business article - November 19, 2026
Evaxion refocuses on cancer vaccines
Evaxion is shifting its strategy to concentrate on immuno-oncology. It will use its AI-Immunology platform to discover new cancer targets and develop cancer vaccines, and it will also make some changes to its organization.
Pharma Business - November 18, 2026
Biovica wins second pharma work order
Biovica has received a second work order, worth about USD 150,000 (about SEK 1.4 million), from one of the world's leading pharmaceutical companies under its recently expanded master services agreement.
Pharma Business - November 16, 2026
AstraZeneca invests SEK 30 million in obesity research
AstraZeneca is investing just over SEK 30 million in four research projects with Karolinska Institutet and Karolinska University Hospital. The five-year investment covers research on obesity and on kidney and liver disease.
Pharma Business - November 13, 2026
EU approves Zealand’s Zeydovio for short bowel syndrome
The European Commission has approved Zealand Pharma's Zeydovio (glepaglutide), a long-acting GLP-2 analog given twice weekly, for adults with short bowel syndrome.
Financing - November 12, 2026
Cereno plans SEK 400 million rights issue
Cereno Scientific plans a rights issue of about SEK 400 million to fund its global Phase IIb study EPIMODE with lead candidate CS1 in pulmonary arterial hypertension (PAH). Warrants included in the issue could bring in up to SEK 400 million more, and the company has also secured extended loan financing of up to SEK 175 million from its lender, Fenja Capital.
Agreement - November 12, 2026
Saniona sells AstronauTx stake for SEK 44.5 million
Saniona has agreed to sell its entire shareholding in AstronauTx to existing AstronauTx investors for GBP 3.36 million (SEK 44.5 million) in cash. The proceeds will help fund Saniona’s two lead programs as they move into Phase 1.